title: Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
abstract: OBJECTIVE
  To evaluate long-term effectiveness and safety of intravitreal injection of ranibizumab as a potential treatment for decreased visual acuity secondary to central retinal vein occlusion.
  
  
  METHODS
  In this prospective interventional case series, patients with central retinal vein occlusion were administered intravitreal ranibizumab 0.5 mg at baseline and monthly for 2 additional doses. Thereafter, the patients were given additional ranibizumab if they had macular edema by optical coherence tomography, leakage during fluorescein angiography, or any intraretinal hemorrhage.
  
  
  RESULTS
  There were 35 eyes of 35 patients who at baseline had a mean visual acuity of 44.2 Early Treatment Diabetic Retinopathy Study letters and a mean central macular thickness of 638 μm. At 12 months, mean visual acuity of 32 eyes improved by 16.5 letters and macular thickness decreased to 164 μm (P < 0.001 vs. baseline for each). At 24 months, mean visual acuity of 24 eyes improved by 17.8 letters and macular thickness was 263 μm (P < 0.001 vs. baseline for each). Patients received an average of 10.2 injections during the first year and 6.6 injections during the second year. No cases of endophthalmitis, retinal detachment, or neovascularization were observed.
  
  
  CONCLUSIONS
  Intravitreal ranibizumab caused a significant improvement in visual acuity and central retinal thickness, which persisted for up to 2 years with minimal side effects.
authors.affiliation: Vitreous-Retina-Macula Consultants of New York, New York, New York, USA.
authors.forename: Louis K
authors.initials: LK
authors.lastname: Chang
authors.forename: Richard F
authors.initials: RF
authors.lastname: Spaide
authors.forename: James M
authors.initials: JM
authors.lastname: Klancnik
authors.forename: John
authors.initials: J
authors.lastname: Sorenson
authors.forename: Jason S
authors.initials: JS
authors.lastname: Slakter
authors.forename: K Bailey
authors.initials: KB
authors.lastname: Freund
authors.forename: Lawrence A
authors.initials: LA
authors.lastname: Yannuzzi
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Tseng
authors.forename: Robert
authors.initials: R
authors.lastname: Klein
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069579:Ranibizumab; D012170:Retinal Vein Occlusion / Q000188:drug therapy* / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014786:Vision Disorders / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity / Q000187:drug effects* / Q000502:physiology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab